Viridian Therapeutics, Inc.

Viridian Therapeutics, Inc.

VRDNNYSE / NASDAQHealthcareSmall cap

$29.96-$1.48 (-4.7%)

Last close · Data as of Nov 20, 2026

Market cap
$1.8B
P/E
-5.3x
EV / EBITDA
-4.9x
Revenue
$70.8M
Net margin
-483.6%
ROCE
-43.9%

+1.7% over the last year

Viridian Therapeutics, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
+33.6%
3M
+22.3%
6M
+69.9%
1Y
+1.7%
5Y
+54.0%

52-week range

Day change -$1.48 (-4.7%) from $31 to $30 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in VRDN, bought on each weekday since 2021.

News & filings

What Viridian Therapeutics filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 343 million US dollars in fiscal 2025.

Strengths (1)

  • Revenue more than doubled in fiscal 2025.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R.

Read moreShow less

Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves' disease and TED. Its portfolio of engineered inhibitors of the neonatal Fc receptor (FcFn) includes VRDN-006, a highly selective Fc fragment, and VRDN-008, a half-life extended bispecific FcRn inhibitor comprising an GC fragment and an albumin-binding domain designed to prolong IGG suppression. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was incorporated in 2010 and is headquartered in Waltham, Massachusetts.

Sector
Healthcare
Shares outstanding
101.8M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$1.8B
P/E
-5.3x
P/B
3.1x
EV / EBITDA
-4.9x
EV / Sales
23.5x
P/S
25.8x
52-week high
$33.78
52-week low
$13.30

Profitability

Operating margin
-512.9%
Net margin
-483.6%
EBITDA margin
-475.9%
ROE
-58.1%
ROCE
-43.9%
ROIC
-47.6%
ROA
-38.1%
Asset turnover
0.08

Growth

Revenue
$70.8M
Revenue growth, 1Y
23359.9%
Revenue CAGR, 3Y
241.9%
Net profit growth, 1Y
26.9%
Free cash flow
-$276.9M

Solvency

Current ratio
12.65
Debt / Equity
0.09
Debt / Assets
0.06
CFO / Net profit
0.81
Cash / Market cap
11.6%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$70.8M
Gross profit$70.8M
Operating expenses$434.3M
Research and development$338.9M
Selling, general and administrative$95.3M
Operating income-$363.4M
Interest and other$20.8M
Pretax income-$342.6M
Tax and other$0.00
Net income-$342.6M

Revenue and net profit

Revenue grew 23359.9% in FY2025; net profit is the dashed line.

Viridian Therapeutics, Inc. revenue and net profit by fiscal year
Viridian Therapeutics, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$1.8M-$129.9M
FY2023$314.0k-$237.7M
FY2024$302.0k-$269.9M
FY2025$70.8M-$342.6M

Cash flows

FY2025: -$276.4M from operations, -$276.9M free after investment (dashed).

Viridian Therapeutics, Inc. operating and free cash flow by fiscal year
Viridian Therapeutics, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$93.8M-$94.6M
FY2023-$184.2M-$185.1M
FY2024-$232.3M-$232.8M
FY2025-$276.4M-$276.9M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$70.8M+23,359.9%1Y
EBITDA
-$337.2M
Net profit
-$342.6M
Cash from operations
-$276.4M
Free cash flow
-$276.9M
Revenue CAGR, 3Y
241.9%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$70.8M-$337.2M-$342.6M-$276.9M-58.1%+23359.9%+26.9%

Monthly returns

Month-by-month returns of VRDN across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$899.4M
Liabilities$177.3M
Equity$722.2M
Paid-in capital$1.9B
Retained earnings-$1.3B

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; VRDN highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

EV / Sales, for the companies without earnings

  1. Viridian Therapeutics, Inc. (this company)23.5x

Not shown (no positive earnings and no EV / Sales): Rapport Therapeutics, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Viridian Therapeutics, Inc.VRDNthis company$1.8B-5.3x3.1x-58.1%-4.9x
Pulse Biosciences, Inc.PLSE$1.9B-25.6x23.1x-90.2%-23.6x
Zymeworks Inc.ZYME$1.8B-22.8x6.9x-30.2%-22.4x
Maravai LifeSciences Holdings, Inc.MRVI$1.8B-14.1x8.7x-61.6%-13.5x
Pediatrix Medical Group, Inc.MD$1.8B11.1x2.1x19.1%7.6x
Vericel CorporationVCEL$1.8B110.3x5.1x4.7%60.3x
ANI Pharmaceuticals, Inc.ANIP$1.8B23.0x3.3x14.5%10.3x
Nuvation Bio Inc.NUVB$1.8B-8.8x5.9x-66.9%-9.0x
Rapport Therapeutics, Inc.RAPP$1.8B—-178.2x-23.0%—
Peer median—-8.8x5.5x-26.6%-9.0x

Year-to-date ROI

VRDN since 1 January, against earlier years.

Historical volatility

VRDN's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Viridian Therapeutics, Inc. operating margin by fiscal year
Viridian Therapeutics, Inc. operating margin by fiscal year
DateOperating margin
FY2022-7587.6%
FY2023-82080.6%
FY2024-99680.0%
FY2025-512.9%
LineFY2025
Operating expensesOperating Expense$434.2M
Research and developmentResearch And Development$338.9M
Total expensesTotal Expenses$434.2M
Pretax incomePretax Income-$342.6M

Learn while you research

Academy chapters picked for Viridian Therapeutics, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Growth Investing23360% revenue growth is in the top tier, learn how to value growth.7 min read
  3. 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  4. 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  5. 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  6. 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →